The Company will also host a conference call and an online presentation on the same day (Tuesday, May 29, 2018) at 09:00 a.m. CET.
The dial-in numbers for the conference call are:
SE: +46 8 5063 9549
UK (and rest if the world): +44 20 3008 9807
The presentation will also be webcast and can be accessed from the following web address:
https://financialhearings.com/event/10809
Hosts: President CEO Kleanthis G Xanthopoulos, Ph.D. and CFO and Deputy CEO Fredrik Alpsten
Investor and Media Contact:
Fredrik Alpsten
CFO and Deputy CEO
+46 706 67 31 06
fredrik.alpsten@irras.com
About IRRAS AB
IRRAS AB (NASDAQ Stockholm: IRRAS) is a publicly-traded, commercial-stage medical technology company focused on developing and commercializing innovative solutions for brain surgery. The Company’s initial product, IRRAflow™, addresses the complications associated with the current treatment methods of intracranial bleeding with a dual lumen catheter that combines active irrigation with ongoing fluid drainage. Regularly during treatment, the catheter is automatically flushed to prevent common catheter occlusions from forming. Additionally, because IRRAflow is a completely closed system, it is designed to reduce the documented infection risk of these procedures.
With its unique product portfolio, protected by property patents and patent applications, IRRAS is well-positioned to establish a leadership position in the medical device market. IRRAS maintains its headquarters in Stockholm, Sweden, with corporate offices in Munich, Germany, and San Diego, California, USA. For more information, please visit www.irras.com.
The information was released for public disclosure, through the agency of the contact person above, on May 28 at 12.00 a.m. (CET).
